Latest MS Stories

John DeLuca, PhD, Vice President for Research at Kessler Foundation presented findings on the use of a behavioral technique for cognitive rehabilitation in people with multiple sclerosis (MS).  Lead investigator was Nancy Chiaravalloti, PhD, director of the Neuropsychology & Neuroscience Laboratory at Kessler Foundation.  The presentation on modified Story Memory Technique was made on October 21, 2011 in Amsterdam at the 5th Joint Triennial Congress of the European and Americas...

SOUTH BEND, Ind., Nov. 16, 2011 /PRNewswire/ -- Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, is pleased to announce its educational sessions for the 2011 Greater New York Dental Meeting November 25-30, 2011 in New York, NY. The meeting convenes world-class clinical leaders, dental professionals and journalists to showcase and discuss the latest and most progressive advancement in cosmetic and other forms of dentistry. Heraeus-supported programs and speakers are as...

ANN ARBOR, Mich., Nov. 14, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (AMEX: AEN), a developer of innovative medicines for serious central nervous system diseases, today reported its third quarter 2011 financial results for the period ended September 30, 2011, as well as updates since the beginning of the third quarter. Updates since the beginning of the third quarter include: Drug Development Programs Relapsing-Remitting Multiple Sclerosis (MS) As of September 19, 2011, the 150th...

MODESTO, Calif., Nov. 14, 2011 /PRNewswire/ -- Today, World Diabetes Day, marks a global effort for awareness and education about the disease, which is expected to affect 8% of the global population by 2025. Adopting healthy eating habits is high on the list of recommendations for diabetes prevention and management.(1) In fact, multiple recent scientific studies have shown that a healthy diet that includes almonds every day shows promise in helping to improve certain...

New drill results include: B5MB4D059 - 10.19 metres @ 6.69% Cu, 0.48 g/t Au, 3.2% Zn & 20 g/t Ag from 33.5 metres in supergene massive sulphides B5MB4D066 - 4.90 metres @ 15.94% Cu, 1.27 g/t Au & 49.4 g/t Ag from 19.3 metres. B5MB4D074 - 35.09 metres @ 4.82% Cu, 0.38 g/t Au, 0.85% Zn & 17.7 g/t Ag from 70.35 metres down hole in a primary massive sulphide intersection TORONTO, Nov. 14, 2011 /PRNewswire/ - Gentor Resources, Inc. ("Gentor" or the "Company") (TSX-V: GNT)...

ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced that the Company's drug candidate, Trimesta(TM) (oral estriol), will be utilized in a new Phase II clinical trial to evaluate its potential therapeutic effect on cognitive dysfunction observed in female multiple sclerosis (MS) patients. The Skirball Foundation and Adeona have pledged to equally support this...

NEW YORK, Nov. 8, 2011 /PRNewswire/ -- VIVMag, the all-digital luxury lifestyle magazine for women, was honored by min's Editorial & Design Awards at an exclusive gala in New York on Nov. 7, taking home coveted awards in two categories. The March/April 2011 issue was recognized in the "Best Digital Magazine Edition" category and the article, "This Is Why You Need the Food Police," featured in the January/February 2011 issue, was recognized in the "Featured Article Online" category....

RICHMOND, Va., Nov. 3, 2011 /PRNewswire/ -- A Continuing Medical Education (CME) workshop, Beating Cardiovascular Disease: Understanding the meaning and value of key risk factors, will be hosted in Jackson, MS on November 19, 2011. "Beating Cardiovascular Disease, a free course with Continuing Medical Education credits, is designed to help doctors eradicate this disease in their practice based upon new and future developments in advanced testing," said Dr. Sam Fillingane, a widely...

ALISO VIEJO, Calif., Nov. 3, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the enrollment of the first patient in the PRIME study. The PRIME study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). "With approximately 400,000 people in the U.S. suffering from MS, there is clearly a need for effective and safe therapies to treat symptoms associated with this...

FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanningâ„¢, reported today the cessation of symptoms in a 41-year-old female patient with multiple sclerosis following noninvasive treatment. The treatment was based on a recent major diagnostic breakthrough about the cause of multiple sclerosis achieved with the advanced FONAR UPRIGHT® MRI. Melville, NY (PRWEB) November 02, 2011 FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanningâ„¢, reported today the cessation...